BLOG

endpoints

Amolyt hauls in €130M round to fund PhIII trial of hypoparathyroidism drug

French-American biotech Amolyt Pharma has raised a €130 million ($138 million) Series C round, planning to use the cash to take its hypoparathyroidism drug into final-stage testing and move another experimental drug into the clinic.